Is hypoglycemia fear independently associated with health-related quality of life?

Health and Quality of Life Outcomes

Nina A Thomas³  Yingnan Zhao¹  Hui Shao²  Lizheng Shi² 

[1]College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, USA

[2]Department of Global Health Systems and Development, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

[3]US Health Services Research, Bristol-Myers Squibb, Princeton, NJ, USA

关键词: Type 2 diabetes;    Quality of life;    Outcome assessment;    Hypoglycemia;    Health status;    Antidiabetic agents;   

Others  :  1144234
DOI  :  10.1186/s12955-014-0167-3

 received in 2014-05-05, accepted in 2014-11-06,  发布年份 2014

【 摘 要 】

Objective

Patients may fear the symptoms and consequences associated with hypoglycemia. We tested whether fear of hypoglycemia is independently associated with poorer health-related quality of life (HRQOL).

Research design and methods

Data were collected using direct-mail survey and enrollment information from adult commercial health plan enrollees with type 2 diabetes during a 12-month period (12/01/2008 to 11/30/2009). HRQOL was evaluated by the EuroQol (EQ)–5D index and 12-item Short Form Health Survey Mental Component Summary (SF-12 MCS) and Physical Component Summary (SF-12 PCS). Fear of hypoglycemia was assessed using the Hypoglycemia Fear Survey (HFS). Two ordinary least-squares (OLS) models of HRQOL controlling for demographics and illness characteristics were specified, and OLS regression coefficients and statistical inferences were compared. Model 1 included 1 variable of hypoglycemia symptoms; Model 2 included both hypoglycemia symptoms and HFS score.

Results

Of 3999 patients contacted, 813 responded to the survey. Model 1: hypoglycemia symptoms alone were associated with worse HRQOL (SF-12 MCS and SF-12 PCS scores and EQ-5D utility score; all P < 0.05). Model 2: hypoglycemia symptoms were significantly associated only with SF-12 MCS score. HFS total score was significantly associated with all 3 HRQOL scores. Hypoglycemia symptoms, Hispanic ethnicity, and longer diabetes duration were associated with greater hypoglycemia fear. Higher income, white race, and treatment without sulfonylurea or insulin were associated with less hypoglycemia fear (all P < 0.05).

Conclusions

In addition to the effect of symptomatic hypoglycemia on HRQOL, fear of hypoglycemia was independently associated with lower overall health status and mental and physical health.

【 授权许可】

   
2014 Shi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Zhao Y, Campbell CR, Fonseca V, Shi L: Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012, 35:1126-1132.
• [2]Zoungas S, Patel A, Chalmers J, De Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Pascal Kengne A, Marre M, Heller S: Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418.
• [3]Hsu PF, Sung SH, Cheng HM, Yeh JS, Liu WL, Chan WL, Chen CH, Chou P, Chuang SY: Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care 2013, 36:894-900.
• [4]Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D: Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008, 10:25-32.
• [5]Marrett E, Stargardt T, Mavros P, Alexander CM: Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab 2009, 11:1138-1144.
• [6]Pollack MF, Purayidathil FW, Bolge SC, Williams SA: Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract 2010, 87:204-210.
• [7]Green AJ, Fox KM, Grandy S: Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract 2012, 96:313-318.
• [8]Williams SA, Pollack MF, Di Bonaventura M: Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011, 91:363-370.
• [9]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
• [10]Brunton SA: Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. Postgrad Med 2012, 124:74-83.
• [11]Cryer PE: Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008, 14:750-756.
• [12]Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L: A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007, 68:10-15.
• [13]Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wandell P: Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype). Diabetes Res Clin Pract 2011, 92:19-25.
• [14]Leiter LA, Yale J, Chiasson J, Harris S, Kleinstiver P, Sauriol L: Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005, 29:186-192.
• [15]Amiel SA, Dixon T, Mann R, Jameson K: Hypoglycaemia in type 2 diabetes. Diabet Med 2008, 25:245-254.
• [16]Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V: The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications 2012, 26:399-406.
• [17]Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
• [18]Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J: Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987, 10:617-621.
• [19]Matza LS, Boye KS, Yurgin N: Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. Health Qual Life Outcomes 2007, 5:47. BioMed Central Full Text
• [20][http://www.euroqol.org] webcite What is EQ-5D? In [].
• [21]Ware J Jr, Kosinski M, Keller SD: A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233.
• [22][http:/ / www.diabetes.org/ living-with-diabetes/ treatment-and-care/ blood-glucose-control/ hypoglycemia-low-blood.html] webcite Living with diabetes. In []
• [23]SAS/STAT® User’s Guide. Version 9.2. SAS Institute Inc, Cary, NC; 2008.
• [24]Wrobel MP, Wystrychowski G, Psurek A, Szymborska-Kajanek A, Strojek K: Association between hypoglycemia and the type of insulin in diabetic patients treated with multiple injections: an observational study. Pol Arch Med Wewn 2014, 124:173-179.
• [25]Pitsillides AN, Anderson SM, Kovatchev B: Hypoglycemia risk and glucose variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of insulin sensitivity and epinephrine counterregulation. Diabetes Technol Ther 2011, 13:11-17.
• [26]Kalra S, Deepak MC, Narang P, Singh V, Maheshwari A: Correlation between measures of hypoglycemia and glycemic improvement in sulfonylurea treated patients with type 2 diabetes in India: results from the OBSTACLE hypoglycemia study. J Postgrad Med 2014, 60:151-155.
• [27]Odawara M, Kadowaki T, Naito Y: Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis. Diabetol Metab Syndr 2014, 6:20. BioMed Central Full Text
• [28]Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care 2013, 36:1384-1395.
• [29]Marrett E, Radican L, Davies MJ, Zhang Q: Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011, 4:251. BioMed Central Full Text
• [30]Sheu WH, Ji LN, Nitiyanant W, Baik SH, Yin D, Mavros P, Chan SP: Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region. Diabetes Res Clin Pract 2012, 96:141-148.
• [31]Stargardt T, Gonder-Frederick L, Krobot KJ, Alexander CM: Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. Health Qual Life Outcomes 2009, 7:91. BioMed Central Full Text
• [32]Solli O, Stavem K, Kristiansen IS: Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes 2010, 8:18. BioMed Central Full Text
• [33]Mitchell BD, Vietri J, Zagar A, Curtis B, Reaney M: Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c. BMC Endocr Disord 2013, 13:59. BioMed Central Full Text